@article{oai:u-ryukyu.repo.nii.ac.jp:02016897,
 author = {宮里, 実 and 有賀, 拓郎 and 前本, 均 and 草田, 武朗 and 芦刈, 明日香 and 上間, 南海子 and 宮城, 亮太 and 仲西, 昌太郎 and 呉屋, 真人 and 村山, 貞之 and 斎藤, 誠一 and Miyazato, Minoru and Ariga, Takuro and Maemoto, Hitoshi and Kusada, Takeaki and Ashikari, Asuka and Uema, Namiko and Miyagi, Ryota and Nakanishi, Shotaro and Goya, Masato and Murayama, Sadayuki and Saito, Seiichi},
 issue = {1-4},
 journal = {琉球医学会誌 = Ryukyu Medical Journal},
 note = {Background: We retrospectively evaluated the outcome of brachytherapy with permanent iodine-125 seed implantation for prostate cancer. Methods: From 2009 to2016, 150 patients（49 in low risk, 81 intermediate, 20 high），mean age 67.1 y, which were performed brachytherapy in our hospital were enrolled in this study. Results: The average prostate volume was 27.4cc, mean International Prostate Symptom Score 9 in these patients. In postplan evaluation, mean prostate V100 93.8%, D90 in brachytherapy alone 173.9Gy, combined with external beam radiation 116.8Gy, rectum V100 in brachytherapy alone 0.27cc, combined with external beam radiation 0.13cc, urethraD90 in brachytherapy alone 89.9Gy, combined with external beam radiation 64.4Gy. The biochemical progression-free survival in 5 years was 97.0% in low risk, while 96.3% in intermediate and no patients in high risk demonstrated PSA relapse during the observation. Migration of seeds was occurred in 3.3%. Adverse event was urinary retention in 2, hematuria in 2, proctitis in 2, rectal bleeding in 2, more than grade 3 was noted in only one patient. Conclusions: The outcome of brachytherapy in our hospital was safe and feasible with low side effects., 論文},
 pages = {13--17},
 title = {限局性前立腺癌に対する I-125 密封小線源療法150例の検討},
 volume = {37}
}